Frontal dysfunction in patients with restless legs syndrome performing a visual oddball task: an event-related potential source imaging study

There is limited understanding of aetiological factors of and treatment options for restless leg syndrome (RLS) in patients with chronic kidney disease (CKD). This study aimed to estimate the prevalence of RLS in CKD patients and identify factors that may contribute to RLS. A questionnaire-based cross-sectional study of patients with CKD stage 4 (CKD 4), pre-dialysis stage 5 (CKD-5ND) and haemodialysis-dependent stage 5 (CKD-5D) was conducted. Eligible patients were enrolled from the local dialysis units and renal clinics. The International RLS Study Group rating scale was used to establish the diagnosis of RLS and quantify its severity. 212 patients with CKD 4 (n = 92), CKD-5ND (n = 14) and CKD-5D (n = 106) were included. The overall prevalence of RLS was 32.1%. Women had a significantly higher odds of having RLS despite adjustment for age, diabetes, cardiovascular disease and whether patients were on dialysis (odds ratio 2.8 [95% confidence intervals 1.5-5.2]). In pre-dialysis groups, patients with RLS had significantly higher serum ferritin (323.9 [SD 338.1] vs 177.5 [SD 178.5]µg/L, p = 0.020) compared to non-RLS patients. In dialysis patients (CKD-5D), those with RLS had significantly higher total white cell (8.0 [SD 3.5] vs 6.8 [SD 1.9] × 109/L, p = 0.026) and neutrophil (6.4 [SD 3.9] vs 4.6 [SD1.7] × 109/L, p = 0.002) counts compared to patients without RLS. RLS remains a significant problem in patients with CKD and may be related to underlying inflammation. Targeting this pathway may be useful. Prevalence of RLS, diagnosed using validated measures, is higher than previous reports. N/A (the current study is not a trial).

Worldwide pooled prevalence of restless legs syndrome in patients with coronary artery disease: A systematic review and meta-analysis.

Objective. Restless legs syndrome is a neurologic disorder which especially affects patients on hemodialysis. The aim of our study was to estimate the frequency and severity of restless legs syndrome in hemodialysis patients' population and explore possible connection with some factors by analyzing differences in patients' sociodemographic characteristics, existence and severity of coexistent diseases, biochemical parameters and dialysis type between the patients with and without this syndrome. Methods. 96 subjects were included in our cross sectional study. The diagnosis of restless legs syndrome was made by using criteria of International Restless Legs Study Group. Severity of the syndrome was evaluated through the use of Restless Legs Syndrome Rating Scale questionnaire. Results. Restless legs syndrome was found in 39.6% of subjects. The most of patients had moderate (36.8%) or severe symptoms (50%). There was no statistically significant difference between the patients with and without restless legs syndrome regarding sociodemographic and biochemical characteristics and dialysis type. In terms of coexistent disease, it was found that patients with restless legs syndrome had a significantly greater frequency of ischemic heart disease and depression compared to the patients without the syndrome. There was no difference in index of coexistent disease. Severity of depression and insomnia was higher in patients with restless legs syndrome. Conclusion. This study confirmed that restless legs syndrome is very frequent in hemodialysis patients and indicated that even two-third of patients had severe to very severe symptoms. For future research, it is necessary to direct attention to influence of comorbidity in hemodialysis patient on restless legs syndrome, especially on influence of psychiatric disorders.

To investigate the prevalence and characteristics of Restless Legs Syndrome (RLS) in patients with Behçet's Disease (BD) and Multiple Sclerosis (MS). Consecutive patients with BD and MS seen in the outpatient clinic were included in the study. As a control group, volunteer subjects without a known peripheral or central nervous system disorder were included. The BD group was divided into two sub-groups as BD with neurological involvement [Neuro-Behçet's Disease (NBD)] and BD without any neurological involvement (other BD) for further evaluation. Data on demographic characteristics, medical history and family history were collected, and all patients underwent neurological examination. The patients were evaluated for the presence of diagnostic criteria for RLS. The features and severity of RLS were evaluated in patients with RLS using Restless Legs Syndrome Identification Form, and the International Restless Legs Syndrome Study Group (IRLSSG) Rating Scale. The clinical and radiological findings of patients with BD and MS were retrieved from their medical files. The study included a total of 96 patients with BD (mean age 39.9±11.8; 51 males; 41 patients with NBD) and 97 patients with MS (mean age 34.97±4.1 years; 24 males). There were 100 healthy control subjects (mean age 36.18±11.10 years; 46 males). RLS was more prevalent in MS (22.8%) and NBD (22%) groups compared to the control group (10%; p=0.004 and 0.029, respectively) with a statistically significant difference. The prevalence of RLS was higher in MS patients with less disability. Most severe RLS symptoms were observed in the MS group. The rate of sleep disorders was also higher in MS group. Although stress appeared to be a factor worsening RLS in all groups, its prevalence was higher in the MS group (p=0.011). There was no correlation between the distribution of magnetic resonance imaging lesions and RLS in both MS and NBD groups. It is well established that RLS can accompany disorders involving the peripheral and central nervous systems such as all types of peripheral neuropathy, myelopathy, and Parkinson's disease. The present study showed that MS and NBD also seem to be a risk factor for RLS, being associated with more severe symptoms.

To evaluate the prevalence of restless legs syndrome (RLS) in patients with chronic obstructive pulmonary disease (COPD) and the relationship between RLS and clinical/laboratory findings of COPD. One hundred and thirty-four COPD patients without secondary causes of RLS were included. Thirty-nine (29.1%) patients were diagnosed with RLS and classified as Group 1. The control group consisted of 65 age-matched COPD patients without RLS. Group 1 was divided into subgroups according to the Johns Hopkins Severity (JHS) scale. Patients with a score of 0, 1, or 2 were classified as JHS 0-2 and those with a score of 3 as JHS 3. Group 1 and the control group and subgroups were compared for clinical and laboratory characteristics. We found that the duration of COPD was longer and that airway obstruction, hypercapnia, and hypoxia were more evident in patients with RLS than those without. Similar differences were also detected between JHS subgroups 3 (more severe) and 0-2. Polyneuropathy frequency was significantly higher in Group 1 compared to controls. However, Group 1 subgroups showed a similar frequency of polyneuropathy. In a multivariate analysis, hypercapnia made a significant independent contribution to both JHS 0-2 and JHS 3 patients when RLS severity was set as the dependent variable. Polyneuropathy and the duration of COPD were significant independent variables for patients in the JHS 3 subgroup. Polyneuropathy was the strongest predictor for the JHS 3 patients. We conclude that RLS is frequent in COPD, particularly in patients with severe hypoxemia/hypercapnia and in late stages of the disease.

Sternberg working memory performance following treatment with pramipexole in patients with moderate-to-severe restless legs syndrome

Clinical characteristics of Restless legs syndrome in patients with Parkinson's disease

Few studies have investigated the mechanisms responsible for the symptoms of restless legs syndrome (RLS). However, these studies were mainly performed during the asymptomatic period and therefore their findings might not apply to changes in sensory processing that occur during the symptomatic period. The objective of this study was to investigate the function of sensory nerve fibres in RLS patients using the current perception threshold (CPT) test during the daytime and in the presence of symptoms. Ninety-three patients with RLS and 34 healthy controls were included in the study. RLS patients were further divided into two subgroups, those who were experiencing RLS symptoms during the CPT test (symptom+) and those without symptoms (symptom-). Demographic data, RLS rating scale score and visual analogue scale were collected. Of the 127 enrolled subjects, CPT values were significantly lower in RLS patients than in controls for all three frequencies. Among the control and RLS subgroups (53 symptom+, 40 symptom-), symptom+ patients showed lower CPT values than controls. This finding indicates a relative hyperaesthetic state in the sensory afferents of peripheral nerves in symptom+ patients. There were no significant differences between the symptom- group and controls. The significantly lower CPT values for all three frequencies in symptom+ patients suggest that central sensory processing disturbance of sensory nerve fibres' input may be involved in the development of symptoms in RLS patients.

To determine the occurrence of symptoms of attention-deficit/hyperactivity disorder (ADHD) in adults with restless legs syndrome (RLS), normal controls, and controls with insomnia. University-based hospital. The occurrence and severity of current ADHD symptoms were determined in a prospective study of sequential adult patients with RLS (n = 62) or insomnia (n = 32) and adult controls (n = 77) using Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) ADHD criteria, the Brown Attention-Deficit Disorder (ADD) Scale for adults, and a structured psychological interview. RLS severity was assessed using the International RLS Study Group Rating Scale (IRLS). Only 1 experimental subject had previously been diagnosed with ADHD. More RLS patients (26%) than insomnia patients (6%) or controls (5%) had ADHD symptoms using age-adjusted total DSM-IV ADHD scores (P < .01). The mean Brown ADD score was greater in RLS patients (37 +/- 28) than in patients with insomnia (24 +/- 18) or controls (21 +/- 18) (P < .01). The RLS symptom severity (0-40 scale) was greater in RLS patients with ADD symptoms (26 +/- 9) than in those without ADD (21 +/- 10) (P < .04). Of the subjects with a Brown ADD score > 40, all reported ADD symptoms in 2 settings, and the majority had had ADHD symptoms since childhood. For subjects with a Brown ADD score > 40, there were no differences between the RLS, insomnia control, and normal control groups in quality of life or the level of anxiety or depression. ADHD symptoms are more common in RLS patients than in patients with insomnia or controls. RLS leg discomfort or poor quality of sleep may theoretically lead to hyperactivity and lack of concentration. Alternatively, RLS and ADHD may be part of a single symptom complex, and dopaminergic deficiency may play a role in both disorders.

The aim of this study is to determine the effect of vitamin D replacement therapy on sleep habits in restless legs syndrome (RLS) patients with vitamin D deficiency. The study was conducted between September 1, 2018, and September 1, 2019, at the Pediatrics outpatient clinic of Bezmialem Vakif University. 46 cases with RLS and 43 healthy controls between these dates were included in the study. The Children's Sleep Habits Questionnare was filled out retrospectively by parents. While vitamin D supplementation was given to 20 children with RLS who were found to have vitamin D deficiency, the 26 patients without vitamin D deficiency did not receive supplementation. There was no significant difference between the treatment groups in terms of gender, age, and pre-treatment sleep habits. Compared to the pre-treatment period, post-treatment bedtime resistance, sleep onset delay, sleep anxiety, parasomnias, daytime sleepiness, and CSHQ total score were significantly improved in RLS cases with vitamin D deficiency. There were no significant differences in RLS patients without vitamin D supplementation. Other comparisons also showed no difference between groups. There was no difference between the sleep habits of RLS cases with and without vitamin D deficiency. Sleep habits improved positively after vitamin D supplementation in patients with vitamin D deficiency compared to the pre-treatment period. There was no difference in the sleeping habits of RLS patients without vitamin D deficiency during the same period. Vitamin D supplementation can improve sleep habits in patients with RLS.

ObjectiveWe investigated the prevalence of restless legs syndrome (RLS) in Japanese patients with type 2 diabetes and assessed the efficacy of pramipexole therapy.DesignOne hundred patients with type 2 diabetes without...

Background &amp; Objectives: Some studies have shown that there is a relationship between restless legs syndrome (RLS) and migraine. Our aim in this study is to investigate the relationship between RLS and migraine and the connection between their etiologies. Methods: This retrospective study was conducted on 109 RLS patients and 105 healthy individuals. Demographic parameters, migraine comorbidity, characteristics of RLS, as well as biochemical and hemogram parameters were examined in the study subjects. Results: The mean age of the RLS patients was 44.28±10.50 years and 38.84% suffered from migraine headaches. RLS was significantly more severe in patients with migraine. Compared to a control group of normal subjects, serum levels of vitamin D, calcium, and iron were significantly lower in RLS patients with or without migraine. The platelet counts, platelet-lymphocyte ratio (PLR), and C-reactive protein (CRP) levels were significantly higher in RLS patients without migraine compared to the control group (p&lt;0.05) Conclusion: RLS was more severe in patients with comorbid migraine. Vitamin D, calcium, and iron levels were significantly lower and inflammation markers were higher in all RLS patients. We think that further investigation of the underlying mechanisms of these two diseases and the results of population- based studies will enable clearer diagnosis and effective treatment of RLS and migraine in the future.

SNCA-Rep1 polymorphism correlates with susceptibility and iron deficiency in restless legs syndrome

Background and PurposeDopamine agonists are first-line drugs for treating the symptoms of restless legs syndrome (RLS). However, few studies have investigated the effect of dopamine agonists on the quality of life (QoL) in RLS patients. We conducted a study to determine whether ropinirole exerts positive effects on the QoL in RLS patients and to analyze the underlying factors.MethodsPrimary RLS patients from eight medical centers were recruited in the study. They were evaluated in the baseline phase using various questionnaires including the Korean versions of the International Restless Legs Scale (K-IRLS), RLS QoL questionnaire (K-RLSQoL), and the Short Form 36 Health Survey (SF-36). After taking ropinirole for 8 weeks the same questionnaires were again completed as a re-evaluation. We analyzed the statistical difference using a paired t-test, a Pearson's correlation, and a stepwise multiple regression in order to identify the factors associated with the QoL change.ResultsA total of 107 subjects, including 65 (60.7%) females, completed this study. They were aged 51.68±14.80 years (mean±SD) and had a symptom duration of 8.8±9.0 months. After treatment with ropinirole, there were significant improvements on the K-RLSQoL, SF-36, and K-IRLS. The Pearson's correlation analysis showed that the improvement of QoL in RLS patients was significantly correlated with the severity of RLS (r=0.236, p<0.014) at baseline.ConclusionsThe results from this study suggest that treatment with ropinirole can improve the QoL in RLS patients. The improvement in the QoL is more related with the improvement of RLS symptoms.

Introduction Insomnia and restless legs syndrome (RLS) are common sleep disorders that may impact obstructive sleep apnea (OSA) treatment. To our knowledge, no studies have investigated whether these comorbidities affect upper airway stimulation (UAS) therapy adherence and outcomes. This study aims to explore possible effects of insomnia and RLS in patients using UAS therapy. Methods All patients who underwent UAS system implantation for treatment of OSA at our facility were retrospectively studied. Pre- and post-implant histories and data, including diagnostic sleep testing, otolaryngology evaluation, activation results, and treatment evaluation, were analyzed. Patients with no insomnia or RLS were compared to patients with insomnia, RLS, or both. Apnea-hypopnea index (AHI), Epworth Sleepiness Scale (ESS), and adherence were compared pre- and post-treatment for each group. Results Sixty-four patients who have undergone UAS implantation at our center have completed post-treatment in-lab titration and evaluation of their UAS system. Insomnia was present in 47%, RLS in 28%, and both insomnia and RLS in 14%. In all groups, the overall AHI during in-lab titration was &amp;gt;50% lower than the pre-treatment AHI (16.1+/-14.3/h vs 32.5+/-13.1/h, p&amp;lt;0.001). While the trend in AHI reductions suggested a lower AHI in those without insomnia or RLS, the reduction did not reach statistical significance (no insomnia or RLS 15.7+/-12.9/h, insomnia 16.9+/-16.7/h, RLS 19.0+/-15.5/h, both insomnia and RLS 23.4+/-18.4/h). UAS therapy usage was reduced in patients with RLS (3.9+/-2.6 h/night, p=0.029) and in patients with both insomnia and RLS (3.9+/-1.3 h/night, p=0.046) compared to patients with neither comorbidity (5.9+/-1.9 h/night). Mean reduction in ESS was similar across groups, averaging from 11+/-5 pre-treatment to 7+/-5 post-treatment (p&amp;lt;0.001). Conclusion Insomnia and RLS are common in patients using UAS therapy for OSA. Pre- and post-treatment residual AHI and ESS significantly improved in all patient groups assessed. A decrease in UAS usage was present in patients with RLS and both RLS and insomnia. Our study suggests that identification and treatment of RLS and insomnia may play an important role for UAS therapy adherence and efficacy, thus, optimizing care. Support (if any):